Barclays analyst Stephanie Davis reiterated a Sell rating on Walgreens Boots Alliance (WBA – Research Report) yesterday and set a price target of $21.00. The company’s shares closed yesterday at $20.71.
According to TipRanks, Davis is an analyst with an average return of -6.5% and a 41.24% success rate. Davis covers the Healthcare sector, focusing on stocks such as Healthequity, TruBridge, and Health Catalyst.
Currently, the analyst consensus on Walgreens Boots Alliance is a Hold with an average price target of $24.67.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $34.19 and a one-year low of $19.45. Currently, Walgreens Boots Alliance has an average volume of 13.65M.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of WBA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Walgreens Boots Alliance (WBA) Company Description:
Retail pharmacy leader Walgreens Boots Alliance (NASDAQ:WBA) operates through its namesake brand Walgreens in the U.S. and Boots in the U.K. In addition, it owns retail and business brands including the No7 Beauty Company, Duane Reade, Ahumada in Chile, and Benavides in Mexico. The company also targets equity investments in healthcare, pharmacy, and retail and has a presence in over 25 countries with more than 450,000 employees.
Read More on WBA:
- Walgreens Boots Alliance price target lowered to $22 from $23 at Leerink
- Unusually active option classes on open March 15th
- Walgreen Boots put volume heavy and directionally bearish
- Claire’s Holdings announces national launch in Walgreens Boots Alliance
- High Benzene Levels Found in Multiple Brands’ Acne Treatments
